Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

@article{Hodi2008ImmunologicAC,
  title={Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.},
  author={Frank Stephen Hodi and Marcus O Butler and Darryl A. Oble and Michael V. Seiden and Frank G. Haluska and Andrea Kruse and Suzanne Macrae and Marybeth Nelson and Christine M. Canning and Israel Lowy and Alan J Korman and David B. Lautz and Sara Russell and Michael Thomas Jaklitsch and Nikhil Himmatsinh Ramaiya and Teresa C. Chen and Donna S Neuberg and James P Allison and Martin C. Mihm and Glenn Dranoff},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 8},
  pages={3005-10}
}
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor destruction in some subjects. Nonetheless, patients that respond also frequently manifest serious inflammatory pathologies, raising the possibility that the therapeutic and toxic effects of CTLA-4 blockade might be linked… CONTINUE READING